Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (3149)	8/30/2002 12:41:41 AM
From: Icebrg	Read Replies (1) of 10345

Andrx granted FDA final marketing approval for Naprelan 28 Aug 2002 The FDA has given Andrx Corporation final marketing approval for a 500mg strength of naproxen sodium, a non-steroidal anti-inflammatory drug, which is bioequivalent to Naprelan. Marketed by Elan Corporation, the 500mg strength of Naprelan had 2001 brand sales of approximately $25 million. Naprelan is used for the treatment of pain caused by arthritis, osteoporosis and other inflammatory conditions. Andrx plans to begin marketing its generic version of Naprelan in September 2002. "We are proud to announce another first for Andrx and we are hopeful that this represents the start of an exciting second half of the year," commented Larry Rosenthal, Andrx's executive vice president of sales and marketing, in a statement to the press. datamonitor.com Posted, just to put a figure on the yearly sales lost. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next